Encorium Group Completes Sale of its U.S. Business to Pierrel Research USA; Announces Manageme...(the risk that we may not have sufficient...)

Date:7/17/2009

the risk that we may not have sufficient funds to operate our business; (ii)our success in attracting new business and retaining existing clients and projects; (iii) the size, duration and timing of clinical trials we are currently managing may change unexpectedly; (iv) the termination, delay or cancellation of clinical trials we are currently managing could cause revenues and cash-on-hand to decline unexpectedly; (v) the timing difference between our receipt of contract milestone or scheduled payments and our incurring costs to manage these trials; (vi) outsourcing trends in the pharmaceutical, biotechnology and medical device industries; (vii) the ability to maintain profit margins in a competitive marketplace; (viii) our ability to attract and retain qualified personnel; (ix) the sensitivity of our business to general economic conditions; (x) other economic, competitive, governmental and technological factors affecting our operations, markets, products, services and prices; (xi) announced awards received from existing and potential customers are not definitive until fully negotiated contracts are executed by the parties; (xii) our backlog may not be indicative of future results and may not generate the revenues expected; (xiii) uncertainties regarding the availability of additional capital and continued listing of our common stock on Nasdaq. You should not place undue reliance on any forward-looking statement. We undertake no obligation to publicly release the result of any revision of these forward-looking statements to reflect events or circumstances after the date they are made or to reflect the occurrence of unanticipated events. Please refer to the section entitled "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2008 and the Company's Quarterly Report on Form 10-Q for the quarterly period ended March 30, 2009 for a more complete discussion of factors which could cause our actual results and financial position to c
'/>"/>

SOURCE Encorium Group, Inc. Copyright©2009 PR Newswire. All rights reserved

2 GOOD

Page: 1 2 3 4
Related biology technology :

1. Encorium Group Updates Expected Timeframe with Respect to the Sale of its U.S. Business
2. Professor Hanna Nohynek Joins Encorium as Head Consultant of its Clinical Vaccine Research Team
3. Encorium Named as Finalist for the Second Annual Vaccine Industry Excellence Award
4. Encorium Group Signs Approximately $2.0 Million of New Business Contracts
5. Encorium Group Signs $3.1 Million of New Business Contracts Including an Extension of a Current U.S. Oncology Clinical Trial with a Major Pharmaceutical Company
6. Encorium Announces Receipt of Letter from Nasdaq Regarding its Third Quarter 2008 Form 10-Q Filing
7. Encorium Reports Third Quarter 2008 Financial Results
8. Encorium Appoints David Ginsberg President and Chief Executive Officer, Announces Changes to the Board of Directors
9. Simcere Pharmaceutical Group Notice of Annual General Meeting
10. Stem Cell Cord Blood Banking Is Huge Global Business for Hospitals, Says CEO of Bio-Matrix Scientific Group Inc.
11. Burnham Institute for Medical Research and Magellan BioScience Group, Inc. Announce Drug Discovery Collaboration